Elanco Enters New Era as Founding Board Leaders Announce Departures

INDIANAPOLIS, IN – February 13, 2026 – Elanco Animal Health is poised for a significant leadership evolution as two foundational board members who guided the company through its formative years as an independent public entity will not seek re-election. The company announced today that R. David Hoover, its first-ever Chairman of the Board, and Dr. Deborah Kochevar, a key scientific voice, will conclude their terms in May at the 2026 Annual Meeting of Shareholders. Their departures mark a pivotal moment for the animal health giant, signaling a transition from its post-spin-off establishment phase to a new era of mature, independent operation.

Following the exits, Elanco's board will consist of nine directors. The change comes as the company enjoys a strong market position, with its stock trading near 52-week highs after an impressive year, suggesting investor confidence in its strategic direction and the planned nature of this transition.

A Foundational Exit

R. David Hoover's departure marks the end of an era for Elanco. Joining in September 2018 as the founding Chairman at the time of the company's IPO, he was instrumental in steering the company out from under the umbrella of its former parent, Eli Lilly and Company. Hoover brought decades of executive experience to the role, having retired as Chairman and CEO of Ball Corporation, and his history as a corporate financial analyst at Eli Lilly gave him unique insight into the company's origins.

Company leadership lauded his contributions as essential to its success. "Dave Hoover's leadership was absolutely foundational to Elanco's success as an independent company," said Lawrence E. Kurzius, who succeeded Hoover as Chairman in 2024 as part of a planned transition. "As our founding Chairman, he skillfully guided us through our spin-off and initial years as a public entity, establishing a robust governance framework and a clear strategic direction. His deep expertise, unwavering commitment, and steady hand were invaluable during a critical period of transformation."

Elanco President and CEO Jeff Simmons echoed this sentiment, crediting Hoover's oversight for the company's current standing. "Dave's advisement and strategic insights were instrumental in shaping Elanco into the global leader it is today, well positioned for our new era," Simmons stated. "I credit much of the exciting runway ahead of Elanco to Dave's oversight and leadership."

For his part, Hoover expressed confidence in the company's trajectory, framing his retirement as timely. "With Elanco in a strong position and an exciting path of sustainable growth and long-term value creation ahead, now is the right time for me to retire," Hoover said. "I am proud to have played a role in Elanco's journey and leave confident in the company's future."

Innovation Leadership in Transition

Also concluding her service is Dr. Deborah Kochevar, who joined the board in March 2019. As the chair of the Innovation, Science and Technology committee, Dr. Kochevar provided a critical link between the board's strategic oversight and the company's core mission of scientific advancement in animal health. Her departure leaves a notable vacancy in scientific expertise at the board level.

Dr. Kochevar's background is deeply rooted in veterinary science and academia. As Dean Emerita of the Cummings School of Veterinary Medicine at Tufts University and a past president of the American College of Veterinary Clinical Pharmacology, she brought a level of scientific and veterinary credibility that was vital for a company whose success hinges on its R&D pipeline.

"We extend our sincere gratitude to Debbie for her significant contributions to the Elanco Board, particularly her leadership of our Innovation, Science and Technology committee," Kurzius said. "Her expertise in veterinary medicine provided critical perspectives that supported the delivery of a robust pipeline focused on transforming animal care."

Simmons highlighted her influence on the company's culture. "Debbie emphasized the importance of a culture of scientific excellence for the creation and maintenance of an innovation pipeline," he added. "Her guidance and support were vital to helping us build our historical innovation momentum... I am extremely grateful for Debbie's expertise and connection to veterinary medicine."

With her departure, the board's Corporate Governance Committee will face the task of identifying how to maintain this high level of scientific oversight as Elanco continues to compete with industry giants like Zoetis and MSD Animal Health on the innovation front.

A Broader Governance Evolution

The departure of two key directors is not happening in a vacuum. It is the latest step in a deliberate, multi-year evolution of Elanco's corporate governance as it matures. The transition began with the planned succession of Kurzius to the Chairman role in 2024, designed to establish a strong, independent, non-executive chairman.

The slimming of the board to nine members follows this trend of strategic refinement. Furthermore, Elanco has been actively implementing shareholder-friendly policies, including a phased declassification of its board, which will see all directors stand for annual election after 2027. The company has also moved to grant shareholders greater rights, such as the ability to call special meetings and amend bylaws, and adopted a majority-voting standard for uncontested director elections. These changes align Elanco with the governance best practices of established public companies and are designed to enhance accountability and investor confidence.

Charting the Course Ahead

With its founding leadership chapter closing, Elanco is charting a course for its next phase of growth. The company has established itself as the fourth-largest player in the global animal health sector, a position solidified by its 2020 acquisition of Bayer Animal Health. It has demonstrated strong performance, surpassing its 2024 innovation revenue targets and boasting a robust pipeline of products aimed at preventing and treating diseases in both farm animals and pets.

The challenges ahead involve navigating a highly competitive market and maintaining the R&D momentum that has been a hallmark of its strategy. The newly composed nine-member board will be tasked with overseeing this strategy, ensuring a seamless transition in innovation leadership, and guiding the company as it leverages its scale and established portfolio to create long-term value. The market's positive reception to the company's performance, even amidst these leadership changes, suggests that investors are focused on the promising future that Elanco's departing founders helped build.